Klinikum Bielefeld

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

  NCT07176312· Phase 2· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Source

• Recruiting

  Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

  NCT07803848· Phase 2· Source

• Recruiting

  NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

  NCT06081244· Phase 3· Source

• Recruiting

  Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

  NCT05904106· Phase 2· Source

• Active, not recruiting

  ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD

  NCT05799963· Source

• Active, not recruiting

  Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

  NCT05689671· Phase 4· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Source

• Recruiting

  Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS

  2024-512320-11-00· Phase 3· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Recruiting

  Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

  NCT05665140· Phase 2/3· Source

• Recruiting

  HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

  NCT04447352· Phase 3· Source

• Active, not recruiting

  Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients

  NCT04246684· Phase 3· Source

• Active, not recruiting

  Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

  NCT04398654· Source

• Recruiting

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and esophageal cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Heart failure1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)

  2022-501850-12-00· Phase 2· Source

• Completed

  Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

  NCT04306315· Phase 4· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Active, not recruiting

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· Phase 3· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Source

• Completed

  Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT03480672· Phase 2· Source

• Active, not recruiting

  Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

  NCT03104842· Phase 2· Source

Trial sites

• Klinikum Bielefeld7 trials
• Klinikum Bielefeld gGmbH22 trials
• Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin0 trials
• Klinikum Bielefeld, Onkologie/Hämatologie/ Palliativmedizin1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Ankylosing spondylitis9 works · 0 trials